文献速递白血病

炎症驱动的JAK/STAT信号激活可逆性加速体外急性髓系白血病

Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro.
PubMed 文献 · Blood Adv · 2020-01-01

该研究在未治疗急性髓系白血病(AML)骨髓中发现炎症细胞因子异常产生,可促进白血病细胞增殖,并激活AML原始细胞及骨髓基质细胞的JAK/STAT信号通路。使用选择性JAK1/2抑制剂芦可替尼在体外显著抑制白血病,但在异种移植模型中单药未取得明显抗白血病活性。

要点

  • 未治疗AML骨髓中炎症细胞因子异常产生并促进白血病细胞增殖。
  • 炎症反应激活AML原始细胞和骨髓基质细胞的JAK/STAT通路。
  • 芦可替尼体外有显著抗白血病活性,但异种移植模型单药活性不明显。

核心结论

  • 未治疗AML骨髓中炎症细胞因子异常产生,通过激活JAK/STAT信号促进白血病增殖,芦可替尼体外有显著抗白血病活性,但异种移植模型单药未取得明显抗白血病活性。

研究设计与样本

  • 体外研究结合异种移植移植模型,检测未治疗AML骨髓炎症细胞因子及JAK/STAT信号。

主要发现

  • 未治疗AML骨髓中炎症细胞因子异常产生,被证明可促进白血病细胞增殖。
  • 炎症反应激活AML原始细胞及骨髓基质细胞的JAK/STAT信号通路,并促进白血病增殖。
  • 使用选择性JAK1/2抑制剂芦可替尼抑制JAK/STAT信号,在体外通过细胞自主和微环境介导机制产生显著抗白血病活性。
  • 在异种移植移植模型中,芦可替尼单药未取得明显抗白血病活性,可能提示JAK1/2抑制在AML中具有互补功能。

局限性

  • 在异种移植移植模型中,芦可替尼单药未取得明显抗白血病活性,可能提示JAK1/2抑制在AML中具有互补功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is characterized by a high relapse rate and dismal long-term overall survival which is related to persistence of leukemia-initiating cells in their niche. Different animal models of myeloid malignancies reveal how neoplastic cells alter the structural and functional characteristics of the hematopoietic stem cell niche to reinforce malignancy. Understanding and disruption of the microenvironmental interactions with AML cells are a vital need. Malignant niches frequently go along with inflammatory responses, but their impact on cancerogenesis often remains unexplored. Here, we uncovered an aberrant production of inflammatory cytokines in untreated AML bone marrow that was proved to promote the proliferation of leukemia cells. This inflammatory response induced an activation of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in AML blasts as well as bone marrow stromal cells that also fostered leukemia proliferation. Inhibition of JAK/STAT signaling using the selective JAK1/2 inhibitor ruxolitinib resulted in significant antileukemic activity in AML in vitro which is mediated through both cell-autonomous and microenvironment-mediated mechanisms. However, in a xenograft transplantation model, monotherapy with ruxolitinib did not achieve substantial antileukemic activity, possibly suggesting a complementary function of JAK1/2 inhibition in AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Habbel J, Arnold L, Chen Y, et al. Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitro. Blood Adv. 2020. PMID: 32614965. doi:10.1182/bloodadvances.2019001292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。